%0 Journal Article
%T Expression of Bcl-2 and Bax in Advanced or Metastatic Prostate Carcinoma
%A Kazem Anvari
%A Mehdi Seilanian Toussi
%A Mahmoud Kalantari
%A Shahram Naseri
%J Urology Journal
%D 2012
%I Shaheed Beheshti University of Medical Sciences
%X Purpose: To evaluate the correlation of Bcl-2 and Bax protein expressions with biochemical failure-free survival in patients with advanced or metastatic prostate carcinoma (PCa) undergoing androgen deprivation therapy. Materials and Methods: This retrospective study was performed on patients with locally advanced (¡Ý T3) or metastatic PCa, who were referred to Omid Hospital between years 2003 and 2007. All subjects had undergone androgen deprivation therapy. Samples were analyzed immunohistochemically for Bax and Bcl-2 expression. The H-score was calculated for each sample based on intensity and percentage of stained cells. H-score > 50 was considered positive. Results: Thirty-seven patients (13 metastatic and 24 locally advanced) were eligible for analysis. Thirty-six (97.3%) samples were positive for Bax and 26 (70.3%) for Bcl-2 expression. The median H-score for Bax and Bcl-2 was 200 (range, 40 to 300) and 85 (range, 0 to 220), respectively. While there was no correlation between Bax expression and Gleason score, high Bcl-2 expression (H-score > 85) was significantly associated with Gleason score > 7 (P = .004). The median time to progression in the advanced and metastatic groups was 22 (range, 10 to 37) months and 16 (range, 9 to 26) months, respectively. High Bcl-2 expression (P = .01) and prostate-specific antigen > 20 ng/mL (P = .01) were significant predictors of lower biochemical progression-free survival. Conclusion: High Bcl-2 expression was associated with higher Gleason scores and lower biochemical-free survival in patients with advanced PCa undergoing androgen deprivation therapy.
%K prostatic neoplasms
%K Bax protein
%K bcl-2
%K disease progression
%K survival
%U http://www.urologyjournal.org/index.php/uj/article/view/1386/631